Since the US FDA officially approved the listing of botulinum toxin type A on December 12, 1989, botulinum toxin has been widely used in ophthalmology, neurology, rehabilitation and other fields to treat strabismus, blepharospasm, More than 30 dystonic diseases, including hemifacial spasm, spastic torticollis, cerebral palsy in children and post-stroke myospasm in adults, are hailed as a major advancement in neurological drugs in the 1990s.

The skin wrinkle-removing effect of botulinum toxin type A was accidentally discovered by J.C., a professor of ophthalmology at the University of British Columbia School of Medicine in Vancouver, Canada, in 1986 while treating blepharospasm. Dermatology professor *** also started research on botulinum toxin type A for skin wrinkle removal, and published the first research paper in 1992, becoming the founder of botulinum toxin type A for beauty.

Since then, after achieving satisfactory results, especially this method that made Hollywood stars younger and more beautiful, Botulinum toxin type A has become popular in the beauty field in the United States, with an annual growth rate of 142%. It is beyond the reach of other methods and has been predicted by authoritative experts as "the main method of beauty and wrinkle removal in the 21st century".